# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $16 t...
Jefferies analyst Dennis Ding maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Hold and lowers the price target from...
Leerink Partners analyst Mani Foroohar maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Market Perform and lowers th...
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an inve...